Loading...
XNAS
PRQR
Market cap198mUSD
May 05, Last price  
1.89USD
1D
-5.03%
1Q
-14.09%
Jan 2017
-61.43%
IPO
-88.45%
Name

ProQR Therapeutics NV

Chart & Performance

D1W1MN
XNAS:PRQR chart
No data to show
P/E
—
P/S
9.29
EPS
—
Div Yield, %
—
Shrs. gr., 5y
14.76%
Rev. gr., 5y
57.79%
Revenues
19m
+190.22%
0313,0009,407,0002,282,000-1,529,0004,941,0001,933,00001,354,0004,037,0006,514,00018,905,000
Net income
-28m
L-1.27%
-3,253,000-12,127,000-20,832,000-39,103,000-43,637,000-36,894,000-56,746,000-46,614,000-61,680,000-64,891,000-28,119,000-27,763,000
CFO
-36m
L
-2,332,000-14,457,000-24,232,000-34,221,000-34,951,000-30,682,000-43,970,000-47,060,000-26,012,000-68,508,00021,548,000-36,393,000
Earnings
May 22, 2025

Profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
URL
https://www.proqr.com/
IPO date
Sep 18, 2014
Employees
130
Domiciled in
NL
Incorporated in
NL

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
18,905
190.22%
6,514
61.36%
4,037
198.15%
Cost of revenue
50,017
41,518
71,994
Unusual Expense (Income)
NOPBT
(31,112)
(35,004)
(67,957)
NOPBT Margin
Operating Taxes
(197)
(78)
96
Tax Rate
NOPAT
(30,915)
(34,926)
(68,053)
Net income
(27,763)
-1.27%
(28,119)
-56.67%
(64,891)
5.21%
Dividends
Dividend yield
Proceeds from repurchase of equity
71,635
347
14,122
BB yield
-33.10%
-0.22%
-5.33%
Debt
Debt current
6,149
1,614
3,887
Long-term debt
23,701
33,562
33,284
Deferred revenue
29,429
44,170
67,012
Other long-term liabilities
Net debt
(119,558)
(83,749)
(58,225)
Cash flow
Cash from operating activities
(36,393)
21,548
(68,508)
CAPEX
(1,418)
(3,646)
(708)
Cash from investing activities
(4,073)
4,278
(702)
Cash from financing activities
70,276
(2,275)
(30,890)
FCF
(28,131)
6,877
(109,286)
Balance
Cash
149,408
118,925
94,775
Long term investments
621
Excess cash
148,463
118,599
95,194
Stockholders' equity
(395,252)
(371,504)
(347,427)
Invested Capital
530,457
476,798
500,405
ROIC
ROCE
EV
Common stock shares outstanding
81,666
81,011
71,641
Price
2.65
33.84%
1.98
-46.49%
3.70
-53.81%
Market cap
216,414
34.92%
160,403
-39.49%
265,073
-48.44%
EV
96,856
76,654
206,464
EBITDA
(28,351)
(32,542)
(65,436)
EV/EBITDA
Interest
1,077
1,203
5,127
Interest/NOPBT